ES2080809T3 - Receptores de factor de necrosis tumoral alfa y beta. - Google Patents

Receptores de factor de necrosis tumoral alfa y beta.

Info

Publication number
ES2080809T3
ES2080809T3 ES90309875T ES90309875T ES2080809T3 ES 2080809 T3 ES2080809 T3 ES 2080809T3 ES 90309875 T ES90309875 T ES 90309875T ES 90309875 T ES90309875 T ES 90309875T ES 2080809 T3 ES2080809 T3 ES 2080809T3
Authority
ES
Spain
Prior art keywords
necrosis factor
tumor necrosis
alpha
factor receptors
beta tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90309875T
Other languages
English (en)
Other versions
ES2080809T4 (es
Inventor
Craig A Smith
Raymond G Goodwin
Patricia M Beckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunex Corp
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27410621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2080809(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of ES2080809T3 publication Critical patent/ES2080809T3/es
Anticipated expiration legal-status Critical
Application granted granted Critical
Publication of ES2080809T4 publication Critical patent/ES2080809T4/es
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REVELAN PROTEINAS RECEPTORAS DEL FACTOR DE NECROSIS TUMORAL, DNAS Y VECTORES DE EXPRESION QUE CODIFICAN LOS RECEPTORES TNF, Y PROCESOS PARA LA PRODUCCION DE RECEPTORES TNF COMO PRODUCTOS DE CULTIVO DE CELDAS RECOMBINANTES
ES90309875T 1989-09-11 1990-09-10 Receptores de factor de necrosis tumoral alfa y beta Expired - Lifetime ES2080809T4 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US40537089A 1989-09-11 1989-09-11
US405370 1989-09-11
US42141789A 1989-10-13 1989-10-13
US421417 1989-10-13
US07/523,635 US5395760A (en) 1989-09-05 1990-05-10 DNA encoding tumor necrosis factor-α and -β receptors
US523635 1990-05-10

Publications (2)

Publication Number Publication Date
ES2080809T3 true ES2080809T3 (es) 1996-02-16
ES2080809T4 ES2080809T4 (es) 2012-12-20

Family

ID=27410621

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90309875T Expired - Lifetime ES2080809T4 (es) 1989-09-11 1990-09-10 Receptores de factor de necrosis tumoral alfa y beta

Country Status (9)

Country Link
US (2) US5395760A (es)
EP (1) EP0418014B1 (es)
AT (1) ATE131871T1 (es)
DE (2) DE10075011I2 (es)
DK (1) DK0418014T3 (es)
ES (1) ES2080809T4 (es)
GR (1) GR3019333T3 (es)
LU (1) LU90591I2 (es)
NL (1) NL300008I2 (es)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US6479632B1 (en) 1988-09-12 2002-11-12 Yeda Research And Development Co. Ltd. Tumor necrosis factor inhibitory protein and its purification
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US6221675B1 (en) 1989-04-21 2001-04-24 Amgen, Inc. TNF receptors, TNF binding proteins and DNAs coding for them
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
ATE289350T1 (de) * 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
US6232446B1 (en) 1989-05-18 2001-05-15 Yeda Research And Development Co. Ltd. TNF ligands
US6262239B1 (en) 1989-05-18 2001-07-17 Yeda Research And Development Co., Ltd. TNF receptor-specific antibodies
ES2072330T5 (es) * 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US5959087A (en) * 1989-08-07 1999-09-28 Peptide Technology, Ltd. Tumour necrosis factor binding ligands
US20030225254A1 (en) * 1989-08-07 2003-12-04 Rathjen Deborah Ann Tumour necrosis factor binding ligands
DE69027121T3 (de) * 1989-08-07 2001-08-30 Peptech Ltd., Dee Why Bindeligande für tumornekrosisfaktor
US6448380B2 (en) 1989-08-07 2002-09-10 Peptech Limited Tumor necrosis factor antibodies
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
ATE194384T1 (de) * 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB2246569A (en) * 1990-06-15 1992-02-05 Charing Cross Sunley Research Tumour necrosis factor - alpha binding protein
US20030064480A1 (en) * 1990-06-28 2003-04-03 Leander Lauffer Fusion proteins with immunoglobulin portions, the preparation and use thereof
US7253264B1 (en) 1990-06-28 2007-08-07 Sanofi-Arentideutschland GmbH Immunoglobulin fusion proteins, their production and use
ES2120949T4 (es) * 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
DK0604418T3 (da) * 1991-03-29 1999-06-14 Immunex Corp Isolerede viralproteincytokinantagonister
AU653937B2 (en) * 1991-04-17 1994-10-20 Medisup International N.V. Water-soluble polypeptides having high affinity for interferons alpha and beta
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
WO1993007863A1 (en) * 1991-10-15 1993-04-29 Mullarkey Michael F Methods and compositions for treating allergic reactions
NZ251820A (en) * 1992-03-30 1996-07-26 Immunex Corp Fusion proteins with tnf-r (tumour necrosis factor-receptor) peptide linked to another tnf-r or an il-1r (interleukin-1-receptor) peptide
JPH07509223A (ja) * 1992-04-30 1995-10-12 アムジェン インコーポレイテッド インターロイキン−１媒介疾患および腫瘍壊死因子媒介疾患の治療方法
IL101769A (en) * 1992-05-03 2007-02-11 Yeda Res & Dev Modulation of TNF receptor action
US20050260201A1 (en) * 1993-01-29 2005-11-24 Centocor, Inc. Methods of treating rheumatoid arthritis using anti-TNF receptor fusion proteins
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6579697B1 (en) * 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
IL111125A0 (en) * 1994-05-11 1994-12-29 Yeda Res & Dev Soluble oligomeric tnf/ngf super family ligand receptors and their use
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5741667A (en) * 1994-05-27 1998-04-21 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US7094564B1 (en) 1995-03-15 2006-08-22 Human Genome Sciences, Inc. Human tumor necrosis factor receptor
US8110659B1 (en) 1995-03-15 2012-02-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like genes
US7078493B1 (en) 1995-03-15 2006-07-18 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like genes
US7427492B1 (en) 1995-06-05 2008-09-23 Human Genome Sciences, Inc. Polynucleotides encoding human tumor necrosis factor receptor-like2
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7070783B1 (en) 1995-05-09 2006-07-04 The Mathilda And Terence Kennedy Institute Of Rheumatology Small molecular weight TNF receptor multimeric molecule
ZA966663B (en) 1995-08-17 1998-02-06 Genentech Inc Traf Inhibitors.
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
US6410252B1 (en) 1995-12-22 2002-06-25 Case Western Reserve University Methods for measuring T cell cytokines
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) * 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
AU2213697A (en) * 1996-03-18 1997-10-10 Medical Science Systems, Inc. A method for periodontal disease treatment
US5912141A (en) * 1996-05-22 1999-06-15 President & Fellows Of Harvard College Nucleic acids encoding tumor virus susceptibility genes
ATE347588T1 (de) 1996-05-23 2006-12-15 Scripps Research Inst Systeme zur präsentation von mhc-antigenen der klasse ii und verfahren zur aktivierung von cd4?+-t-lymphozyten
TW555765B (en) * 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US5939281A (en) * 1996-09-16 1999-08-17 Case Western Reserve University Detecting alloreactivity
EP0961782A4 (en) * 1996-10-30 2003-07-16 Human Genome Sciences Inc RECEPTOR TR2 FROM THE TUMORNCROSIS FACTOR-RECEPTOR FAMILY.
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
US6930084B1 (en) 1996-11-06 2005-08-16 The Regents Of The University Of California Treating arthritis with TNF receptor releasing enzyme
BR9712900A (pt) 1996-11-06 2000-11-28 Univ California Enzima liberadora de receptor de fator de necrose de tumor isolado, composições que compreendem a enzima e métodos de utilização da mesma
ES2326347T3 (es) 1996-11-27 2009-10-07 Immunex Corporation Metodo para regular la produccion de oxido nitrico.
JP2001513754A (ja) 1996-12-06 2001-09-04 アムジェン インコーポレイテッド Ｔｎｆ媒介疾患を処置するためのｔｎｆ結合タンパク質を使用する組み合わせ治療
JP4771563B2 (ja) 1996-12-06 2011-09-14 アムジエン・インコーポレーテツド Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
AU2472899A (en) * 1998-01-27 1999-08-09 Millennium Pharmaceuticals, Inc. Novel molecules of the tnf receptor superfamily and uses therefor
US20030180310A1 (en) * 1998-04-29 2003-09-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US8197430B1 (en) * 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
US6620382B1 (en) 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7294481B1 (en) 1999-01-05 2007-11-13 Immunex Corporation Method for producing recombinant proteins
US7109292B2 (en) * 1999-03-08 2006-09-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE60040147D1 (de) * 1999-05-28 2008-10-16 Targeted Genetics Corp Methoden und zusammensetzungen zur reduktion des tumor-nekrosis-faktor-spiegels (tnf) bei tnf-assoziierten erkrankungen
EP1939300A1 (en) 1999-05-28 2008-07-02 Targeted Genetics Corporation Methods and compositions for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
US7122631B2 (en) * 2000-02-22 2006-10-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP2003525612A (ja) 2000-03-02 2003-09-02 ゼンコー ＴＮＦ−α関連障害の処置のための変種ＴＮＦ−αタンパク質の設計および発見
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
ATE366306T1 (de) 2000-09-22 2007-07-15 Immunex Corp Screeningverfahren für agonisten und antagonisten des rezeptoraktivators von nf-kappa b
MXPA03007316A (es) 2001-02-19 2003-12-04 Merck Patent Gmbh Metodo para la identificacion de epitopes de celulas t y el uso para la preparacion de moleculas con inmunogenicidad reducida.
US20030040119A1 (en) * 2001-04-11 2003-02-27 The Regents Of The University Of Michigan Separation devices and methods for separating particles
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
WO2003026695A1 (en) * 2001-09-21 2003-04-03 Genset S.A. Agonists and antagonists of cylixin for the treatment of metabolic disorders
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003059935A2 (en) * 2001-12-21 2003-07-24 Immunex Corporation Methods for purifying protein
PT1946776T (pt) 2002-02-27 2017-03-17 Immunex Corp Composição de tnfr-fc estabilizada compreendendo arginina
US6872549B2 (en) 2002-03-27 2005-03-29 Immunex Corporation Methods for increasing polypeptide production
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
DE60333228D1 (de) * 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
AU2003299971A1 (en) 2002-12-30 2004-07-29 Amgen Inc. Combination therapy with co-stimulatory factors
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CN101039957A (zh) 2003-05-16 2007-09-19 因特缪恩公司 合成的趋化因子受体配体及其使用方法
US7892563B2 (en) * 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
HRP20130098T1 (hr) 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
US7407973B2 (en) * 2003-10-24 2008-08-05 Intermune, Inc. Use of pirfenidone in therapeutic regimens
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
CA2576030A1 (en) * 2004-08-09 2006-02-23 Alios Biopharma Inc. Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same
US7597884B2 (en) * 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
TWI364458B (en) * 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
MX2007015476A (es) 2005-06-14 2008-02-25 Amgen Inc Formulaciones de proteina autoamortiguadoras.
US20070065514A1 (en) * 2005-09-22 2007-03-22 Howell Mark D Method for enhancing immune responses in mammals
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
KR101789603B1 (ko) * 2005-11-10 2017-11-21 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Ｔｎｆ 수퍼패밀리 수용체에 대한 스플라이스 스위칭올리고머 및 염증성 질환 치료용 약제학적 조성물
US7504106B2 (en) * 2006-03-14 2009-03-17 Boris Skurkovich Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
WO2007149115A1 (en) * 2006-06-15 2007-12-27 Targeted Genetics Corporation Methods for treating target joints in inflammatory arthritis using aav vectors encoding a tnf antagonist
CA2697784A1 (en) * 2006-07-07 2008-01-10 Bioassets Development Corporation Novel regimens for treating diseases and disorders
US20080075690A1 (en) * 2006-09-22 2008-03-27 Mark Douglas Howell Method for enhancing immune responses in mammals
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US20090264353A1 (en) * 2007-10-19 2009-10-22 Santaris Pharma A/S Splice Switching Oligomers for TNF Superfamily Receptors and their Use in Treatment of Disease
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
PL2148691T3 (pl) 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego
CA2679941C (en) 2007-03-02 2016-09-20 Wyeth Use of copper and glutamate in cell culture for production of polypeptides
JP5628790B2 (ja) 2008-04-07 2014-11-19 バイエル・ヘルスケア・エルエルシー 糖タンパク質の組換え生産の方法
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
JP2013512674A (ja) 2009-12-02 2013-04-18 アクセルロン ファーマ， インコーポレイテッド Ｆｃ融合タンパク質の血清半減期を増加させるための組成物および方法
HRP20171939T1 (hr) 2010-01-15 2018-03-23 Kirin-Amgen, Inc. Formulacija protutijela i režimi terapije
SG10201505217WA (en) 2010-07-09 2015-08-28 Biogen Hemophilia Inc Chimeric clotting factors
EP2601287B1 (en) 2010-08-05 2015-01-07 Amgen Inc. Dipeptides to enhance yield and viability from cell cultures
CN105177032B (zh) * 2010-09-01 2019-05-10 山东新时代药业有限公司 新型人肿瘤坏死因子受体-Fc融合基因及其产物蛋白
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
DK2726600T3 (en) 2011-07-01 2017-05-15 Amgen Inc Mammalian Cell Culture
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
AU2012301656A1 (en) 2011-09-02 2014-01-16 Amgen Inc. Pharmaceutical product and method of analysing light exposure of a pharmaceutical product
US11707409B2 (en) 2011-10-25 2023-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US10350139B2 (en) 2011-10-25 2019-07-16 Corning Incorporated Pharmaceutical glass packaging assuring pharmaceutical sterility
AR089231A1 (es) 2011-12-15 2014-08-06 Amgen Inc Metodo de floculacion
EA031324B1 (ru) 2012-09-11 2018-12-28 Кохерус Байосайенсис, Инк. Правильно свернутый этанерцепт с высокой чистотой и высоким уровнем выхода
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
EP3395423B1 (en) 2013-03-14 2023-09-20 Amgen Inc. Removal of leaked affinity purification ligand
TWI771890B (zh) 2013-03-14 2022-07-21 美商安美基公司 用於增加重組蛋白質之甘露糖含量之方法
AR095527A1 (es) 2013-03-15 2015-10-21 Biogen Idec Inc Formulaciones de polipéptido fc-factor ix
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2 (en) 2013-04-24 2017-07-25 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717649B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2 (en) 2013-04-24 2017-12-12 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2 (en) 2013-04-24 2017-08-01 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9481901B2 (en) 2013-05-30 2016-11-01 Amgen Inc. Methods for increasing mannose content of recombinant proteins
HUE071397T2 (hu) 2013-10-31 2025-08-28 Amgen Inc Monenzin alkalmazása rekombináns fehérjék glikozilációjának szabályozására
EP3094735A1 (en) 2014-01-13 2016-11-23 Amgen Inc. Regulating ornithine metabolism to manipulate the high mannose glycoform content of recombinant proteins
JP6474420B2 (ja) 2014-01-29 2019-02-27 アムジエン・インコーポレーテツド 組換えタンパク質のグリコシル化を調節するためのｎ−グリコシル化経路制御因子の過剰発現
US10106829B2 (en) 2014-01-29 2018-10-23 Amgen Inc. Overexpression of N-glycosylation pathway regulators to modulate glycosylation of recombinant proteins
US20170174772A1 (en) 2014-03-31 2017-06-22 Kirin-Amgen, Inc. Methods of treating nail and scalp psoriasis
PT3152317T (pt) 2014-06-04 2019-04-18 Amgen Inc Métodos de colheita de culturas de células de mamíferos
ES2727380T3 (es) 2014-11-19 2019-10-15 Amgen Inc Cuantificación de resto glucano en glucoproteínas recombinantes
ES2784503T3 (es) 2014-12-01 2020-09-28 Amgen Inc Procedimiento para manipular el nivel de contenido de glicano de una glicoproteína
KR20170138426A (ko) 2015-03-13 2017-12-15 삼성바이오에피스 주식회사 항-tnf-알파 폴리펩티드 조성물 및 그 용도
AU2017345490B2 (en) 2016-10-21 2022-07-07 Amgen Inc. Pharmaceutical formulations and methods of making the same
IL321253A (en) 2018-05-01 2025-08-01 Amgen Inc Antibodies with a modulated glycan profile
US11952399B2 (en) 2018-12-18 2024-04-09 Amgen Inc. Methods for purifying proteins
KR20240128067A (ko) 2021-12-29 2024-08-23 브리스톨-마이어스 스큅 컴퍼니 랜딩 패드 세포주의 생성
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675285A (en) * 1984-09-19 1987-06-23 Genetics Institute, Inc. Method for identification and isolation of DNA encoding a desired protein
JPS61293924A (ja) * 1985-06-23 1986-12-24 Asahi Chem Ind Co Ltd 生理活性物質の受容タンパク
US4935233A (en) * 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
IL83878A (en) * 1987-09-13 1995-07-31 Yeda Res & Dev Soluble protein corresponding to tnf inhibitory protein its preparation and pharmaceutical compositions containing it
US5512544A (en) * 1987-09-13 1996-04-30 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising an anticytokine
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
DE68926888T2 (de) * 1988-01-22 1997-01-09 Zymogenetics Inc Verfahren zur Herstellung von sekretierten Rezeptoranalogen
GB8806339D0 (en) * 1988-03-17 1988-04-13 Hoffmann La Roche Monoclonal antibodies
GB8807803D0 (en) * 1988-03-31 1988-05-05 Glaxo Group Ltd Biochemical product
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
EP0394827A1 (en) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
DE3922089A1 (de) * 1989-05-09 1990-12-13 Basf Ag Neue proteine und ihre herstellung
ES2072330T5 (es) * 1989-05-18 2013-06-24 Yeda Research And Development Co., Ltd. Proteínas de unión II al Factor de Necrosis Tumoral, su purificación y anticuerpos frente a los mismos
IL95031A (en) * 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
NZ235148A (en) * 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
ATE194384T1 (de) * 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
ES2120949T4 (es) * 1990-06-28 2011-12-29 Sanofi-Aventis Deutschland Gmbh 50% Proteinas de fusión con porciones de inmunoglobulinas, su preparación y empleo.
GB9022648D0 (en) * 1990-10-18 1990-11-28 Charing Cross Sunley Research Polypeptide and its use
IL99120A0 (en) * 1991-08-07 1992-07-15 Yeda Res & Dev Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them
US5447851B1 (en) * 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells

Also Published As

Publication number Publication date
DE69024291D1 (de) 1996-02-01
DE10075011I1 (de) 2003-06-12
GR3019333T3 (en) 1996-06-30
US5395760A (en) 1995-03-07
EP0418014B1 (en) 1995-12-20
NL300008I2 (nl) 2000-12-01
EP0418014A1 (en) 1991-03-20
DE10075011I2 (de) 2004-08-12
LU90591I2 (fr) 2000-07-31
ES2080809T4 (es) 2012-12-20
USRE36755E (en) 2000-06-27
NL300008I1 (nl) 2000-08-01
DE69024291T2 (de) 1996-10-31
ATE131871T1 (de) 1996-01-15
DK0418014T3 (da) 1996-01-22

Similar Documents

Publication Publication Date Title
ES2080809T3 (es) Receptores de factor de necrosis tumoral alfa y beta.
CA2065346A1 (en) Tumor necrosis factor-.alpha. and-.beta. receptors
ES2172502T3 (es) Receptores tipo ii de interleucina 1.
ES2103706T3 (es) Receptores de interleuquina-4.
EP0318296A3 (en) Interleukin-1 receptors
NO872988L (no) Pattedyr-interleukin-4.
ATE365796T1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
DE69022559D1 (de) Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).
DE69016508D1 (de) Interleukin-7-Rezeptoren.
DE3851035D1 (de) Interleukin-7.
DK0494260T3 (da) Receptorer for granulocytkolonistimulerende faktor

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 418014

Country of ref document: ES

SPCF Request for supplementary protection certificate filed

Free format text: ETANERCEPT (ENBREL)

Spc suppl protection certif: C200000014

Filing date: 20000630

SPCG Supplementary protection certificate granted

Free format text: ETANERCEPT (ENBREL)

Spc suppl protection certif: C200000014

Filing date: 20000630

Expiry date: 20150203

Effective date: 20040311